TAK compared with PAX: revenue, margins and what each company keeps, and the suppliers and customers both name

TAKTakeda Pharmaceutical Co Ltd

Mkt capRevenueRevenue

PAXPatria Investments Ltd

Mkt capRevenueRevenue

Compare

TAKTakeda Pharmaceutical Co Ltd

PAXPatria Investments Ltd

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

TAK: latest quarter not drawable. PAX: latest quarter not drawable.Method ›

Price

rebased to 0%

TAK, solidPAX, dashed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only TAK 17

NBIXNeurocrine Biosciencescustomer

EXELExelixissupplier

PTGXProtagonist Therapeuticssupplier

DNLIDenali Therapeuticssupplier

13 more · TAK chain ›

Shared 0

No shared counterparties.

Only PAX 13

—KPMG Auditores Independentes Ltdaunlistedsupplier

—Maples Corporate Servicesunlistedsupplier

—Nasdaq Global Select Marketunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—The Depository Trustunlistedsupplier

9 more · PAX chain ›

TAKTakeda Pharmaceutical Co Ltd

20.76· pre 20.78· delayed

Mkt cap$35.8B

PAXPatria Investments Ltd

9.37· pre 9.37· delayed

Pre-marketNov 4 '26delayed

Mkt cap$1.5B

Compare

Pre-marketNov 4 '26delayed

TAKTakeda Pharmaceutical Co Ltd

PAXPatria Investments Ltd

20.76pre 20.78delayed

Price

9.37pre 9.37delayed

$35.8B

Mkt cap

$1.5B

TAK20.76vsPAX9.37Pre-marketNov 4 '26delayed